CCC launches regulatory compliance portal

Share this article:

Responding to the billions of dollars in industry fines paid under the False Claims Act, The Center for Communication Compliance (CCC) has launched a new online compliance portal. 

Chaired by former FDA employee Wayne Pines, the CCC portal offers regulatory compliance tests (RCTs) online. Current RCTs available on the website range from $100 for an “advanced test,” and $300 for a “basic test.” Public relations RCTs are available now, with advertising and promotional medical education RCTs launching in September, according to CCC president and founder Ilyssa Levins. Participants scoring higher than 80% on the test will receive a certificate of “regulatory compliance competency.”

Public relations agencies Weber Shandwick and Porter Novelli have both committed to certifying their healthcare staff in all US offices, according to a company statement. In addition to the RCT certification, healthcare professionals can purchase consulting packages for reviewing campaign materials, from the initial campaign conception, to programing and actual ads, notes Levins.

Advisory board members at CCC include Jill Alvarez, JD, partner, Nixon Peabody Technology and Intellectual Property Group, Alan Bennett, JD, managing partner at Ropes & Gray, Glenn Byrd, MBA, RAC, director of regulatory affairs at MedImmune, and Dr. John Kamp, executive director of the Coalition for Healthcare Communication, among others.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?